Remove Obesity Remove Pharmacology Remove Risk Factors
article thumbnail

Exploring Obesity and the Latest Advances in Weight Loss Drugs during Healthy Weight Week

Cardiometabolic Health Congress

In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.

Obesity 97
article thumbnail

Protein Drug Targets for Abdominal Aortic Aneurysm and Proteomic Associations Between Modifiable Risk Factors and Abdominal Aortic Aneurysm

Journal of the American Heart Association

BackgroundAbdominal aortic aneurysm (AAA) is a severe aortic disease for which no pharmacological interventions have yet been developed. Colocalization analysis pinpointed 13 proteins with strong evidence of colocalization with AAA. Further investigations are needed to clarify the specific roles of these proteins in AAA pathology.

article thumbnail

Call for papers! Special Edition on Cardiometabolic Diseases

International Journal of Cardiovascular Sciences

The term cardiometabolic risk describes the chances that a person has of damaging the cardiovascular system when one or more risk factors appear together. These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome.

article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59
article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 52
article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52